Used in targeted cancer therapies, particularly for glioblastoma and other solid tumors overexpressing IL-13Ra2. This antibody serves as a key component in chimeric antigen receptor (CAR) T cell therapies, enabling immune cells to recognize and destroy tumor cells expressing the IL-13Ra2 receptor. It has been utilized in clinical trials to develop immunotherapies with potential for treating recurrent or resistant brain cancers. Additionally, it supports diagnostic applications by helping identify tumor tissues with high IL-13Ra2 expression, aiding in patient selection for targeted treatments.